CN101020059B - Medicine composition containing docetaxel matter and its preparation process - Google Patents
Medicine composition containing docetaxel matter and its preparation process Download PDFInfo
- Publication number
- CN101020059B CN101020059B CN2006100238886A CN200610023888A CN101020059B CN 101020059 B CN101020059 B CN 101020059B CN 2006100238886 A CN2006100238886 A CN 2006100238886A CN 200610023888 A CN200610023888 A CN 200610023888A CN 101020059 B CN101020059 B CN 101020059B
- Authority
- CN
- China
- Prior art keywords
- docetaxel
- pharmaceutical composition
- cyclodextrin
- injection
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title claims abstract description 135
- 229960003668 docetaxel Drugs 0.000 title claims abstract description 127
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims description 63
- 239000003814 drug Substances 0.000 title description 23
- 229940079593 drug Drugs 0.000 title description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 28
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 26
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 150000001413 amino acids Chemical class 0.000 claims abstract description 12
- 238000010253 intravenous injection Methods 0.000 claims abstract description 7
- 239000002904 solvent Substances 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 66
- 239000000243 solution Substances 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 20
- 238000004108 freeze drying Methods 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 12
- 235000001014 amino acid Nutrition 0.000 claims description 11
- 239000004471 Glycine Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 4
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 229960003104 ornithine Drugs 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 235000009697 arginine Nutrition 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 235000014393 valine Nutrition 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- 150000004625 docetaxel anhydrous derivatives Chemical class 0.000 claims 2
- 238000002604 ultrasonography Methods 0.000 claims 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1
- 238000002347 injection Methods 0.000 abstract description 43
- 239000007924 injection Substances 0.000 abstract description 43
- 230000000694 effects Effects 0.000 abstract description 9
- 231100000331 toxic Toxicity 0.000 abstract description 7
- 230000002588 toxic effect Effects 0.000 abstract description 7
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000005303 weighing Methods 0.000 description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 27
- 238000012360 testing method Methods 0.000 description 27
- 239000012530 fluid Substances 0.000 description 26
- 238000000034 method Methods 0.000 description 24
- 239000013558 reference substance Substances 0.000 description 21
- 206010028980 Neoplasm Diseases 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 14
- 238000012856 packing Methods 0.000 description 14
- 235000002639 sodium chloride Nutrition 0.000 description 11
- 241000700199 Cavia porcellus Species 0.000 description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 10
- 229930195725 Mannitol Natural products 0.000 description 10
- 230000001476 alcoholic effect Effects 0.000 description 10
- 239000000594 mannitol Substances 0.000 description 10
- 235000010355 mannitol Nutrition 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 9
- 208000003455 anaphylaxis Diseases 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 229940063683 taxotere Drugs 0.000 description 8
- 206010002198 Anaphylactic reaction Diseases 0.000 description 7
- 229960002668 sodium chloride Drugs 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000036783 anaphylactic response Effects 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 230000000172 allergic effect Effects 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 238000013112 stability test Methods 0.000 description 5
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical class CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- -1 polyoxyethylene Polymers 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 102000029749 Microtubule Human genes 0.000 description 3
- 108091022875 Microtubule Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940088529 claritin Drugs 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000002185 docetaxel anhydrous group Chemical group 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002216 Anaphylactoid reaction Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229940121849 Mitotic inhibitor Drugs 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种适合于静脉注射的含多烯紫杉醇类物质的药物组合物及其制备方法，该药物组合物以多烯紫杉醇或它的盐或水合物为活性成分，采用环糊精和氨基酸联合作为增溶剂。利用本发明药物组合物制成的注射剂具有稳定性良好，毒副作用低等优点。The invention relates to a pharmaceutical composition containing docetaxel suitable for intravenous injection and a preparation method thereof. The pharmaceutical composition uses docetaxel or its salt or hydrate as an active ingredient, and adopts cyclodextrin and amino acid Combined as a solubilizer. The injection prepared by using the pharmaceutical composition of the invention has the advantages of good stability, low toxic and side effects, and the like.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition that contains docetaxel matter, refer to that more specifically a kind of is the medicinal composition for injections of active component with Docetaxel or its salt or hydrate.The invention still further relates to the preparation method of said composition.
Background technology
Docetaxel matter is the chemical compound that a known class has remarkable active anticancer, belong to mitotic inhibitor, by promoting the microtubule dimer to be assembled into microtubule, simultaneously by preventing that the multimerization process from making microtubule stable, the retardance cell is in G2 and M phase, thus the mitosis of anticancer and propagation.This class medicine is all effective for advanced breast cancer, nonsmall-cell lung cancer, ovarian cancer, carcinoma of prostate, cancer of pancreas, hepatocarcinoma, incidence cancer, gastric cancer etc.
Because Docetaxel is insoluble in water, the dissolubility of Docetaxel in water only is 0.5 μ g/ml under the room temperature, therefore at present commercially available Docetaxel injection mainly is that Tween 80 or polyoxyethylene hydrogenated Oleum Ricini with high concentration are the formulated concentrated solution of solubilizing agent, include ethanol or add the ethanol of (in the packing capsule subsidiary again 1) 13%, the injection back is to the human body toxic side effect.Tween 80 or polyoxyethylene hydrogenated Oleum Ricini are the surfactants of using always, but Tween 80 or polyoxyethylene hydrogenated Oleum Ricini have very strong toxicity and high anaphylaxis, tween 80 has hemolytic, be used for intravenous injection, can cause severe anaphylactic reaction, comprise shock, dyspnea, hypotension, angioedema, anaphylactoid reaction symptoms such as rubella, therefore before using the Docetaxel injection, must take Claritin or injection Claritin earlier and help to alleviate the toxic and side effects such as serious allergy that the use owing to the Docetaxel injection produces, usually bring misery, directly influenced the use of this medicine to patient.In addition, though tween 80 or polyoxyethylene hydrogenated Oleum Ricini can increase the dissolubility of Docetaxel, at the Docetaxel poor stability of solution state, effect duration is short; Subsidiary 1 13% ethanol has also increased production cost in the packing capsule.Therefore, change the dosage form of Docetaxel, increase the water solublity of Docetaxel, eliminate the focus that anaphylaxis that is caused by solvents such as tween 80s and the toxic and side effects that reduces Docetaxel self become present research.
Many researcheres are studied the untoward reaction that reduces docetaxel matter and cause in clinical practice and the toxic and side effects of himself, and for example Chinese patent application 02155476.5 discloses and adopted hyaluronic acid, glucose or mannitol, ethanol, propylene glycol, non-ionic surface active agent to prepare the injection of docetaxel matter; It is the compositions that solvent prepares docetaxel matter that United States Patent (USP) 97/196,934 discloses with dimethyl acetylamide, Polyethylene Glycol, is used for parenterai administration; Australian Patent 35544/93 discloses the dissolubility that the branched cyclodextrin that uses unsaturated cyclodextrin and enzyme modification can appropriateness increases docetaxel matter; Chinese patent ZL98811010.5 adopts acetylation cyclodextrin and HP-and other water solublity adjuvant to prepare the injection preparation of docetaxel matter; Chinese patent application 03112082.2 is adopting cyclodextrin, water solublity adjuvant and organic acid and acylate to prepare the injection preparation of docetaxel matter as adjuvant, the stability of resulting injection makes moderate progress, but the content of docetaxel matter descends still near 10% in 6 hours, and add organic acid and acylate owing to contain, the pH value of preparation low excessively (pH value is 3～5) easily produces tangible blood vessel irritation when intravenous injection is used.Utilize the injection of the docetaxel matter that prior art obtains mostly to exist stable dissatisfactory defective.
Summary of the invention
The purpose of this invention is to provide a kind of have good stability and toxic and side effects little, be suitable for the intravenous pharmaceutical composition of docetaxel matter that contains to overcome the existing in prior technology defective.
Another object of the present invention is to provide this preparation of drug combination method.
The characteristics of pharmaceutical composition of the present invention are with cyclodextrin and aminoacid as solubilizing agent.Use aminoacid and cyclodextrin to increase the dissolubility of Docetaxel in water by uniting, stop medicine to separate out gathering, increase its physical stability and chemical stability.
By weight, the pharmaceutical composition that contains docetaxel matter of the present invention comprises:
1 part of docetaxel matter
Cyclodextrin 40-200 part
0.2～10 part in aminoacid
The said docetaxel matter of the present invention is meant chemical compound Docetaxel or its salt or hydrate.Said cyclodextrin is HP-or acetyl-gamma-cyclodextrin, and said aminoacid is glycine, valine, aspartic acid, glutamic acid, arginine, ornithine, lysine, tyrosine or histidine.
The pharmaceutical composition that contains docetaxel matter of the present invention refers to the dried frozen aquatic products after aqueous liquid medicine composition or its lyophilization.Preparation of drug combination method of the present invention may further comprise the steps:
(1) successively aminoacid and cyclodextrin are dissolved in the water;
(2) add docetaxel matter or be dissolved in alcoholic acid docetaxel matter;
(3) ultrasonic or be stirred to the solution clear and obtain fluid composition, or
(4) fluid composition is carried out lyophilization and obtain dried frozen aquatic products.
In the said method, by weight, the consumption of water is 50-1000 a times of docetaxel matter, and consumption of ethanol is 1-100 a times of docetaxel matter; Can also use caffolding agent during the preparation dried frozen aquatic products, caffolding agent can be selected mannitol, lactose, glucose, sucrose, dextran or its mixture for use; The dried frozen aquatic products that said method obtains can be quickly dissolved in the aqueous solution of water for injection or sodium chloride-containing, glucose, mannitol, dextran etc. for loose block or powder, obtains the solution of clear.
Pharmaceutical composition of the present invention is suitable for making intravenous injection, and by the administration of intravenous drip mode, the administration process of its lyophilized formulations can be finished in 2 hours.Effective using dosage of pharmaceutical composition of the present invention is the 2mg/kg body weight.
Beneficial effect
1, pharmaceutical composition of the present invention is solubilizing agent with aminoacid and cyclodextrin, toxic and side effects is low, need not treat in advance before the administration by Claritin or other medicine, not only made things convenient for administration, also increased compliance of patients, reduced cost, pharmaceutical composition of the present invention is to the blood vessel nonirritant, and intravenous administration suits.
2, having good stability of pharmaceutical composition of the present invention, fluid composition was placed 28 hours down at 4 ℃, and the changes of contents of its Docetaxel is less than 2%; The pharmaceutical composition of dried frozen aquatic products form the aqueous solution room temperature under can stablize and deposit at least 24 hours, Docetaxel does not have to assemble separates out, its concentration change is less than 2%.
3, simple, the easily control of preparation of drug combination technology of the present invention is fit to industrialized great production.
The specific embodiment
The present invention is further elaborated below in conjunction with specific embodiment, but do not limit the present invention.
Among the following embodiment, adopt the HPLC method to measure Docetaxel content, chromatographic condition: mobile phase is acetonitrile one water (60: 40, v/v), flow velocity is 1.0ml/min, and sample size is 15 μ l, column temperature is 25 ℃, adopt UV-detector, the detection wavelength is 229nm, chromatographic column adopting octadecylsilane chemically bonded silica post.
Among the following embodiment, remove and specify, the method that the lyophilization fluid composition obtains dried frozen aquatic products is: behind the packing fluid composition, do not seal the metal dish of putting into freeze drying box, and temperature is reduced to-30 ℃, the metal dish that preparation will be housed is rapidly put into freeze drying box, keeps 7 hours, making the vacuum in the case then is 0.2Pa, again shelf is heated up, and be controlled at below the eutectic point-3 ℃, kept 12 hours, be warming up to 4 ℃ at last, and kept 8 hours, formulation temperature is overlapped with shelf temperature, put into aseptic filtering gas, the water content of control preparation is sealed rapidly and can be obtained dried frozen aquatic products 3%.
Embodiment 1
Precision takes by weighing the 40mg Docetaxel and is dissolved in 1ml ethanol.In addition precision takes by weighing the 30mg glycine and is dissolved in the 5ml water, adds the alcoholic solution that 3g HP-dissolving back adds Docetaxel, ultrasonic 20min, stir clear solution, be fluid composition.
Embodiment 2
Precision takes by weighing the 40mg Docetaxel and is dissolved in 0.5ml ethanol.Precision takes by weighing the 20mg aspartic acid and is dissolved in the 10ml water, adds the alcoholic solution that 4g HP-dissolving back slowly adds Docetaxel, ultrasonic 30min, placed again 1 hour, obtain clear solution, after every bottle of quantitative 2ml packing, lyophilization obtains dried frozen aquatic products.
Embodiment 3
Precision takes by weighing the 6g HP-and is dissolved in the 20ml 0.2% arginine aqueous solution, places on the magnetic force heating stirrer.Precision takes by weighing Docetaxel 80mg in addition, behind the 1ml dissolve with ethanol, slowly be added drop-wise in the mixed solution of HP-and smart glycine, continue to stir 5h under the room temperature, add 7.5% mannitol and 5% lactose (w/v, aqueous solution), after every bottle of quantitative 5ml packing, lyophilization obtains dried frozen aquatic products.
Embodiment 4
Take by weighing Docetaxel 40mg, add the 0.5ml dissolve with ethanol; Other precision takes by weighing the 2g HP-and is dissolved in the histidine aqueous solution of 10ml 0.2%, put 20 ℃ of constant temperature water-soluble in, stir and inject the Docetaxel alcoholic solution down, continue to stir 2h,-30 ℃ of following pre-freezes, put dry 24h in the vacuum freeze dryer, get the pulverous dried frozen aquatic products of white solid.
Embodiment 5
Taking by weighing the 20g HP-is dissolved in the glutamic acid aqueous solution of 50ml 0.2%, other precision takes by weighing the 200mg Docetaxel and is dissolved in the 5ml ethanol, slowly be injected in the mixed solution of above-mentioned cyclodextrin and glutamic acid, supersound process 30min, placed again 1 hour, obtain fluid composition, after every bottle of quantitative 1ml packing, lyophilization obtains dried frozen aquatic products.
Embodiment 6
Precision takes by weighing 400mg sulphuric acid Docetaxel and is dissolved in 10ml ethanol.In addition precision takes by weighing the 300mg valine and is dissolved in the 5ml water, add 30g acetyl-gamma-cyclodextrin dissolving back and add the alcoholic solution of sulphuric acid Docetaxel, ultrasonic 20min, stir clear solution, be fluid composition.
Embodiment 7
The three water Docetaxels that precision takes by weighing 200mg are dissolved in 5ml ethanol.In addition precision takes by weighing 300mg lysine and is dissolved in the 5ml water, add 30g acetyl-gamma-cyclodextrin dissolving back and add the alcoholic solution of three water Docetaxels, ultrasonic 20min, stir clear solution, be fluid composition.
Embodiment 8
The Docetaxel that precision takes by weighing 200mg is dissolved in 5ml ethanol.In addition precision takes by weighing 300mg tyrosine and is dissolved in the 5ml water, add 30g acetyl-gamma-cyclodextrin dissolving back and add the alcoholic solution of Docetaxel, ultrasonic 20min, stir clear solution, be fluid composition.
Embodiment 9
The Docetaxel that precision takes by weighing 200mg is dissolved in 5ml ethanol.Other precision takes by weighing 300mg tyrosine and is dissolved in the 5ml water, add 30g acetyl-gamma-cyclodextrin dissolving back and add the alcoholic solution of Docetaxel, ultrasonic 20min, stir clear solution, obtain fluid composition, add 5% mannitol (w/v, aqueous solution) again, after every bottle of quantitative 1ml packing, lyophilization obtains dried frozen aquatic products.
Embodiment 10
The Docetaxel that precision takes by weighing 300mg is dissolved in 5ml ethanol.In addition precision takes by weighing the 200mg glycine and is dissolved in the 5ml water, add 30g acetyl-gamma-cyclodextrin dissolving back and add the alcoholic solution of Docetaxel, ultrasonic 20min, stir clear solution, be fluid composition.Add 5% mannitol (w/v, aqueous solution) again, after every bottle of quantitative 1ml packing, lyophilization obtains dried frozen aquatic products.
The mensuration of the saturation solubility of embodiment 11 fluid compositions
Taking by weighing the 3g HP-is dissolved in the glycine solution of 10ml 0.2%, other precision takes by weighing the 40mg Docetaxel and is dissolved in the 0.5ml ethanol, slowly be injected in the mixed solution of above-mentioned cyclodextrin and glycine, supersound process 30min, placed again 1 hour, obtain fluid composition, carry out the mensuration of saturation solubility: get above-mentioned fluid composition and each 1mL of Docetaxel raw material, put respectively under 30 ℃, the 40r/min 48h that vibrates, lyophilization adds water 1mL, vortex 30s, 3000r/min is centrifugal, behind 0.22 μ m membrane filtration, suitably carry out liquid phase analysis after the dilution with mobile phase, sample size is 20 μ L, mobile phase is acetonitrile: water (60: 40), flow velocity is 1mL/min, measures peak area, calculates the saturated concentration of Docetaxel in water.The results are shown in Table 1.
Table 1
As shown in Table 1, the present composition is compared with the Docetaxel raw material, and the dissolubility of Docetaxel in water increased by 8000 times, with the Docetaxel of the script slightly solubility Yi Rong that becomes.Experiment shows, among the present invention HP-and glycine unite the dissolubility that use can significantly improve Docetaxel, solved the difficult problem in the preparation Docetaxel injection.
The stability test of embodiment 12 fluid compositions
Precision takes by weighing the 400mg Docetaxel and is dissolved in 1ml ethanol.In addition precision takes by weighing the 200mg glycine and is dissolved in the 40ml water, adds the alcoholic solution that 20g HP-dissolving back adds Docetaxel, ultrasonic 30min, stir clear solution, be fluid composition of the present invention.
Above-mentioned prepared fluid composition adds in an amount of distilled water and dilutes, and is mixed with the settled solution that Docetaxel content is 1mg/ml.4 ℃, 25 ℃ and 35 ℃ of placements, respectively at 8,12,16,20,24 and 28h sampling, the HPLC method is measured Docetaxel content, the results are shown in Table 2 with this solution.
Table 2
The result shows that fluid composition of the present invention is placed 28h, changes of contents＜2% at 4 ℃; Deposit 24h at ambient temperature, changes of contents＜2%; Place 24h at 35 ℃, lowering of concentration is lower than 2%, is not higher than in ambient temperature under 35 ℃ the situation, and this fluid composition can keep the above stability of 24h, shows having good stability of fluid composition of the present invention.
The stability test of embodiment 13 dried frozen aquatic products state combination things
Precision takes by weighing the 300mg glycine and is dissolved in the 4ml water, add 30g HP-dissolving back and add the 400mg Docetaxel, 25 ℃ are stirred 5h, obtain clear solution, add 10% mannitol (w/v again, aqueous solution), after every bottle of quantitative 0.5ml packing, lyophilization promptly gets dried frozen aquatic products.From in appearance, dried frozen aquatic products is off-white color lyophilizing block or powder.
It is an amount of to get the above-mentioned dried frozen aquatic products that makes, and sealing is placed in 25 ℃ and to be carried out accelerated test June, in 0,1,2,3, measure indexs such as outward appearance, related substance, content June again, estimates the stability of dried frozen aquatic products.The results are shown in Table 3.
In the table, related substance is pressed the HPLC method and is measured, and content is for being equivalent to labelled amount.
Table 3
The result shows that Docetaxel composition freeze-drying product were placed 6 months at 25 ℃, and its outward appearance, relevant medicine and content do not have significant change, show that Docetaxel composition freeze-drying product have good stability.
The stability test of embodiment 14 dried frozen aquatic products state combination things
Test sample: the dried frozen aquatic products state combination thing of pressing the preparation of embodiment 5 methods
Reference substance: press the liquid Docetaxel compositions of Chinese patent 98811010.5 methods preparation, add 5% mannitol (w/v, aqueous solution), obtain dried frozen aquatic products by every bottle of quantitative 1ml packing postlyophilization.The preparation method of its fluid composition is: take by weighing the 20g HP-and be dissolved in the 20ml water, add the 400mg Docetaxel, 25 ℃ are stirred 3h, obtain clear solution, obtain fluid composition.
Docetaxel injection (Docetaxel for Injection, 20mg/ props up, available from Shanghai City pharmaceuticals)
Get each 3 of test sample, reference substance and Docetaxel for Injection, be dissolved in respectively in the 5ml water, be diluted to 1mg/ml with the sodium-chloride water solution of 0.9%w/v respectively then; Other gets each 3 of test sample, reference substance and Docetaxel for Injection, be dissolved in respectively behind the 5ml water respectively that the D/W with 5%w/v is diluted to 1mg/ml, placing the clarity of checking test sample, reference substance and Docetaxel for Injection on the the 0th, 2,4,8,12,24 hour respectively.The results are shown in Table 4.
Table 4
As can be seen from Table 4, dried frozen aquatic products state combination thing of the present invention does not see after 24 hours that through the dilution of sodium-chloride water solution and D/W medicine separates out, and reference substance dilutes with 0.9% sodium-chloride water solution and began to have small amount of drug to separate out in back 2 hours, commercially available Docetaxel injection also began have small amount of drug separate out in 2 hours with sodium-chloride water solution dilution 4 hours with the D/W dilution.Show that dried frozen aquatic products state combination thing diluent of the present invention has good physical stability, is enough to satisfy the needs of vein treatment.
The stability test of embodiment 15 dried frozen aquatic products state combination things
Taking by weighing the 20g HP-is dissolved in the histidine aqueous solution of 50ml 0.3%, other takes by weighing the 200mg Docetaxel and is dissolved in the 1.5ml ethanol, slowly be injected in the mixed solution of above-mentioned cyclodextrin and histidine, supersound process 30min, placed again 1 hour, obtain the Docetaxel composition solution, can obtain dried frozen aquatic products by every bottle of quantitative 5ml (containing Docetaxel 20mg) packing postlyophilization.
Each 3 of the above-mentioned dried frozen aquatic productses that makes are dissolved in respectively in the sodium chloride or 5%w/v D/W of 20ml0.9%w/v, prepare the settled solution that Docetaxel concentration is about 1mg/ml respectively.The sodium-chloride water solution that contains the present composition and the D/W that prepare are contained in the sealed glass container, placed 6 hours in 35 ℃, in the concentration of sampling in the 0th, 2,4,8,12,24 hour by Docetaxel in the HPLC analytic sample, analysis result sees Table 5 respectively.
Table 5
Experimental result shows that the present composition was placed 24 hours down at 35 ℃, Docetaxel concentration almost constant (＜2%), and promptly the Docetaxel composition stable is good.
The stability test of embodiment 16 dried frozen aquatic products state combination things
Taking by weighing the 40g HP-is dissolved in the ornithine aqueous solution of 10ml 0.3%, other takes by weighing the 400mg Docetaxel and is dissolved in the 1.5ml ethanol, slowly be injected in the mixed solution of above-mentioned cyclodextrin and ornithine, supersound process 30min, placed again 1 hour, obtain the Docetaxel composition solution, can obtain dried frozen aquatic products by every bottle of quantitative 5ml (containing Docetaxel 20mg) packing postlyophilization.
Reference substance: press the liquid Docetaxel compositions of Chinese patent 98811010.5 methods preparation, add 5% mannitol (w/v, aqueous solution), after every bottle of quantitative 1ml packing, lyophilization obtains dried frozen aquatic products.The preparation method of its fluid composition is with embodiment 14.
Respectively above-mentioned dried frozen aquatic products that makes and reference substance are added in an amount of normal saline or the 5%w/v D/W, preparation Docetaxel concentration is about the settled solution of 1mg/ml, the normal saline that contains the present composition or reference substance and the D/W that prepare are at room temperature deposited, measured the concentration of Docetaxel in each solution with HPLC every 12 hours, analysis result sees Table 6.
Table 6
Experimental result shows, at room temperature placed 24 hours, contain the normal saline of compositions of Chinese patent 98811010.5 methods preparations and the Docetaxel concentration in the 5% glucose diluent and all descended 10%, Docetaxel concentration does not almost change in the sample diluting liquid of the present composition and contain.Illustrate that the stability of the present composition is better than the compositions of prior art report.
The inhibition test of embodiment 17 dried frozen aquatic products state combination things
Trial drug: press the dried frozen aquatic products state combination thing of embodiment 13 methods preparation, being diluted to Docetaxel concentration with an amount of normal saline during test is 8mg/ml.
Positive reference substance: Docetaxel injection (Docetaxel for Injection, 20mg/ props up, available from Shanghai City pharmaceuticals)
Negative control product: sterile saline
Preparation mouse mastopathy cell EMT-6 suspension makes every milliliter of suspension contain 5 * 107 cancerous cell.Get BALB/C mice, 6 every group, every Corium Mus is inoculation 0.2ml down, carries out administration by dosage shown in the table 7 after 24 hours behind the inoculated tumour, once a day, and continuous 5 days.Wherein the subcutaneous or abdominal cavity of test group gives trial drug, subcutaneous or the abdominal cavity of positive controls gives the Docetaxel injection, subcutaneous or the abdominal cavity of negative control group gives isopyknic sterile saline, each treated animal is execution in the 12nd day behind inoculated tumour, get the tumor back of weighing and calculate Docetaxel compositions and the Docetaxel injection suppression ratio to tumor, it is heavy that average tumor is organized in the average tumor weight-treatment of suppression ratio %=[(matched group)/the average tumor weight of matched group] * 100%.The result is as shown in table 7:
Table 7
Result of the test shows, the subcutaneous tumour inhibiting rate that gives the present composition is 44.7～53.0%, tumour inhibiting rate behind the intraperitoneal administration is 41.8～44.3%, the tumour inhibiting rate that gives the present composition of same dose and Docetaxel injection under the identical administering mode is suitable, shows that the present composition has the good antitumor effect.
The inhibition test of embodiment 18 dried frozen aquatic products state combination things
Trial drug: press the dried frozen aquatic products state combination thing of embodiment 13 methods preparation, being diluted to Docetaxel concentration with an amount of normal saline during test is 8mg/ml;
Positive reference substance: the taxotere concentrated injection, being diluted to Docetaxel concentration with normal saline during test is 8mg/ml;
Negative control product: normal saline
Lewis lung cancer is inoculated in 30 BDF1 mices, press dosage shown in the table 8 behind the inoculated tumour respectively once at the 1st, 3,5,7 each intraperitoneal injection of day interval, wherein test group is injected Docetaxel composition freeze-drying product, positive controls injection taxotere injection, the isopyknic normal saline of negative control group lumbar injection, the execution in the 12nd day behind inoculated tumour of each treated animal is dissected, and gets and calculates the suppression ratio of trial drug to tumor after tumor is weighed.The result is as shown in table 8:
Table 8
Body is interior but the tumor result shows Docetaxel pharmaceutical composition of the present invention to be compared with the taxotere injection, has suitable antitumor activity.
The irritation test of embodiment 19 dried frozen aquatic products state combination things
Trial drug: press the dried frozen aquatic products state combination thing of embodiment 13 methods preparation, being diluted to Docetaxel concentration with an amount of normal saline during test is 1mg/ml;
Reference substance 1: the liquid Docetaxel compositions by the preparation of Chinese patent application CN1535678A method, add 5% mannitol (w/v, aqueous solution), obtain dried frozen aquatic products by every bottle of quantitative 1ml packing postlyophilization.The preparation method of its fluid composition is: take by weighing the 20g HP-and be dissolved in the 20ml water, add the 400mg Docetaxel, 25 ℃ are stirred 3h, obtain clear solution, add Chinese holly edge acid adjust pH to 3.5 again, obtain fluid composition behind the mixing.
Reference substance 2: Docetaxel injection (Docetaxel for Injection, 20mg/ props up, available from Shanghai City pharmaceuticals)
Get 15 of rabbit, be divided into three test group, inject (2mg/kg) trial drug, reference substance 1 and reference substance 2 respectively, after the sacrificed by exsanguination, observe the response situation of injection site at auricular vein or the quadriceps femoris of each test group rabbit.The rabbit erythrocyte suspension of preparation 2% adds trial drug, observes it to erythrocytic influence.The results are shown in Table 9.
Table 9
Annotate: the blood vessel irritation reaction is not found in "-" expression in the table; "+" expression has the blood vessel irritation reaction.
Result of the test shows that irritative response in various degree all appears in the rabbit after reference substance 1 and reference substance 2 injections, as redness, hyperemia, inflammatory infiltration etc.And to behind rabbit vein or the intramuscular injection pharmaceutical composition of the present invention, perusal there is no irritant reaction such as redness, hyperemia, through pathological examination, symptoms such as fibrinoid necrosis, inflammatory infiltration do not appear, and the present composition is no haemolysis coacervation in observing time, and the present composition intravenous administration that suits is described.
The toxicity test of embodiment 20 dried frozen aquatic products state combination things
Trial drug: press the Docetaxel pharmaceutical composition dried frozen aquatic products of embodiment 13 methods preparation, being diluted to Docetaxel concentration with an amount of normal saline during test is 8mg/ml;
Reference substance: the taxotere concentrated injection, being diluted to Docetaxel concentration with normal saline during test is 8mg/ml;
Get 60 of the kunming mices of body weight 18～22g sex unanimity, be divided into 6 groups at random, 10 every group, respectively get 3 groups and be included into test group and matched group respectively, an intravenous injection present composition of test group dried frozen aquatic products, an intravenous injection taxotere of matched group injection.Dosage is arranged by geometric progression between group, ratio observe at 1: 0.8 and record administration 10 days in the reaction and the mortality rate of each treated animal, calculate LD, its credible being limited to of 95% with simplifying probit method:
Taxotere injection LD50=107mg ± 32mg/kg,
Docetaxel composition freeze-dried powder LD50=219mg ± 30mg/kg of the present invention.
The experimental result of LD50 shows that present composition dried frozen aquatic products is compared with the taxotere injection, and toxicity obviously reduces.
The sensitivity test of embodiment 21 dried frozen aquatic products state combination things
Trial drug and reference substance are with embodiment 20.
Medication: get 12 of Cavia porcelluss, be divided into 2 groups at random, 6 every group, male and female half and half.For test group and matched group, with the dosage of 10mg/kg body weight, intramuscular injection trial drug and reference substance 0.2～0.3mL inject every other day respectively, continuous 3 times, observe the untoward reaction of Cavia porcellus behavior and appearance.The injection back is the 7th day first, respectively gets 3 Cavia porcelluss in test group and the matched group, and lumbar injection 2～3mL trial drug and reference substance are attacked respectively, and observation injection back Cavia porcellus has or not and allergic symptom occurs.Remaining second half Cavia porcellus is injected the trial drug or the reference substance of back 14 days lumbar injection same doses in first, and carries out allergic symptom and observe.
Judge index: the allergic symptom difference according to two groups of Cavia porcellus reactions is divided into 1～4 grade.0 grade: no significant reaction; One-level: have and slightly grab nose, perpendicular hair; Secondary: have and significantly grab nose, perpendicular hair, tremble or sneeze; Three grades: repeatedly continuously sneeze, with dyspnea or spasm, tic; Level Four: spasm, tic, gatism, shock, death.
The symptoms of allergic observed result: tangible anaphylaxis appears in the matched group Cavia porcellus, promptly occurs grabbing nose and gatism phenomenon after the 1st administration; Occur serious gatism, perpendicular hair and tic phenomenon after the 2nd administration, every Cavia porcellus all has proctoptosis phenomenon in various degree.The test group Cavia porcellus only occurs individually after the 3rd administration that gatism, lethargy are depressed, activity reduces phenomenon.Matched group is injected dead 3 of back for the first time, after the abdominal cavity was attacked in the 14th day 2 Cavia porcellus death is arranged, and has tangible anaphylaxis and signs of toxicity.Anaphylaxis does not appear in test group when intramuscular injection, even find no allergic symptom behind heavy dose of lumbar injection yet.The result shows that caused anaphylaxis degree of Docetaxel pharmaceutical composition of the present invention and mortality rate are starkly lower than the taxotere injection.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100238886A CN101020059B (en) | 2006-02-15 | 2006-02-15 | Medicine composition containing docetaxel matter and its preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100238886A CN101020059B (en) | 2006-02-15 | 2006-02-15 | Medicine composition containing docetaxel matter and its preparation process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101020059A CN101020059A (en) | 2007-08-22 |
| CN101020059B true CN101020059B (en) | 2011-01-05 |
Family
ID=38707985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006100238886A Expired - Fee Related CN101020059B (en) | 2006-02-15 | 2006-02-15 | Medicine composition containing docetaxel matter and its preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101020059B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102584633B (en) * | 2011-12-16 | 2013-07-03 | 山东大学 | Lysine alpha-amino carbobenzoxy high-efficiency selective protection method and product thereof |
| CN102755325B (en) * | 2012-07-04 | 2013-05-29 | 深圳信立泰药业股份有限公司 | Cefoxitin sodium medicinal composition, powder injection and preparation method thereof |
| CN111728941A (en) * | 2015-03-16 | 2020-10-02 | 湖南省金准医疗科技有限公司 | Pharmaceutical compositions containing taxane-cyclodextrin complexes, methods of manufacture and methods of use |
| CN106924179B (en) * | 2015-12-29 | 2021-04-30 | 成都康弘药业集团股份有限公司 | Liquid preparation containing Vonoprazan fumarate and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1281373A (en) * | 1997-11-10 | 2001-01-24 | 西森实验室有限公司 | Pharmaceutical compositions containing cyclodextrins and taxoids |
| CN1568178A (en) * | 2001-09-10 | 2005-01-19 | 中外制药株式会社 | Injectable composition of paclitaxel |
| CN1660073A (en) * | 2004-12-30 | 2005-08-31 | 中国科学院上海药物研究所 | A kind of docetaxel nanoparticle and preparation method thereof |
-
2006
- 2006-02-15 CN CN2006100238886A patent/CN101020059B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1281373A (en) * | 1997-11-10 | 2001-01-24 | 西森实验室有限公司 | Pharmaceutical compositions containing cyclodextrins and taxoids |
| CN1568178A (en) * | 2001-09-10 | 2005-01-19 | 中外制药株式会社 | Injectable composition of paclitaxel |
| CN1660073A (en) * | 2004-12-30 | 2005-08-31 | 中国科学院上海药物研究所 | A kind of docetaxel nanoparticle and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101020059A (en) | 2007-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2353488T3 (en) | COMPOSITION OF PACLITAXEL LIPOSOMES FOR THE TREATMENT OF CANCER, AND ITS PREPARATION. | |
| Fan et al. | Plasma membrane targeted photodynamic O2 economizer for hypoxic tumor therapy | |
| CN110870868A (en) | Pharmaceutical composition containing methylene blue dye, nutrient or/and anti-tumor compound and application thereof | |
| Shang et al. | Dual cancer stem cell manipulation to enhance phototherapy against tumor progression and metastasis | |
| CN101351219A (en) | Stable formulations comprising a synergistic ratio of interferon gamma and alpha | |
| JPS6248629A (en) | Anthracycling glycoside solution | |
| Gu et al. | Reversal of hepatic fibrosis by the co-delivery of drug and ribonucleoprotein-based genome editor | |
| Qiu et al. | Res@ ZIF-90 suppress gastric cancer progression by disturbing mitochondrial homeostasis | |
| CN105688220A (en) | Pharmaceutical composition containing butylphthalide and novel solubilizer | |
| JP5723031B2 (en) | Liquid medicinal composition containing Mikafungin, an echinocandin antifungal agent | |
| CN105380906B (en) | A kind of Cabazitaxel cancer target lipidosome injection and preparation method thereof | |
| CN101020059B (en) | Medicine composition containing docetaxel matter and its preparation process | |
| CN101700229B (en) | Alprostadil long-circulating lipid microsphere preparation for intravenous injection and preparation method thereof | |
| CN106456475A (en) | Thickening composition containing lipid peptide type compound | |
| JP6389958B2 (en) | Medicinal use of anti-tumor for rutile pentacyclic triterpene saponins | |
| Ji et al. | GSH-activable and cytolytic iPep-coupled immune nanoagonist for cancer synergetic therapy | |
| CN109453123A (en) | A kind of Combretastatin analog derivative freeze-dried powder and preparation method thereof | |
| CN105078904B (en) | A kind of Cabazitaxel lipid microspheres albumin freeze-dried powder and preparation method thereof | |
| Yuan et al. | In vivo metabolizable branched poly (ester amide) based on inositol and amino acids as a drug nanocarrier for cancer therapy | |
| Ding et al. | All-stage targeted nanodiscs for glioma treatment by inducing cuproptosis and apoptosis of cancer cells and cancer stem cells | |
| CN103356492A (en) | Tripterine pharmaceutical composition using albumin as pharmaceutical carrier | |
| CN105853378A (en) | Resveratrol trinocotinate nanocrystal quick release capsule preparation and preparation technology thereof | |
| CN101167718B (en) | Oridonin A powder injection and preparation method thereof | |
| CN1762341B (en) | Salvianolic acid compound for treating cardiovascular and cerebrovascular disease and liver disease, and application thereof | |
| CN102526714B (en) | Medicine composition for curing tumour and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110105 Termination date: 20210215 |